Is the Supreme Court’s Abortion Pill Ruling Actually a Feint? |
Sign up for Executive Dysfunction, a newsletter that highlights one under-the-radar story each week about how Trump is changing the law—or how the law is pushing back. You’ll also receive updates on the latest from Slate’s Jurisprudence team.
Last week the Supreme Court temporarily ended the latest crisis around mifepristone, a drug used in most abortions nationwide, but one thing remains clear: Some conservative judges are tempted to reenter the fray on reproductive rights, despite Justice Brett Kavanaugh’s promise that in overturning Roe, the court was getting out of the abortion business.
The case involved a challenge brought by Louisiana to a 2023 Food and Drug Administration decision allowing telehealth access to the drug. Louisiana contended that the FDA had inadequately reviewed safety risks in removing the in-person dispensing requirement, and the conservative 5th Circuit Court of Appeals agreed, blocking telehealth access nationwide as the litigation continued. At the request of mifepristone’s manufacturers, Danco and GenBioPro, the Supreme Court agreed to stay the 5th Circuit’s order until it issues a final decision in the case.
But don’t be fooled into believing that the threat to mifepristone is over. The anti-abortion movement is still working through the courts and through the Trump administration to impose national limits on mifepristone that voters would never endorse. As importantly, the Louisiana case provides clear evidence that a campaign that presents itself as pro-woman is actually just pro-punishment.
There are now several cases attacking mifepristone in the lower courts, some of them more ambitious than Louisiana’s. The attorneys general of Texas, Florida, Missouri, Idaho, and Kansas are all challenging FDA regulation of mifepristone. Individual lawsuits brought by........